Generalized brain and skin proteasome inhibition in Huntington's disease

Annals of Neurology

Volumn 56, Issue 3, 2004, Pages 319-328

  Seo, Hyemyung ^a   Sonntag, Kai Christian ^a   Isacson, Ole ^a  

^a MCLEAN HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BRAIN DERIVED NEUROTROPHIC FACTOR; HUNTINGTIN; NUCLEAR PROTEIN; PROTEASOME INHIBITOR; PROTEIN SUBUNIT; UBIQUITIN;

ARTICLE; BRAIN REGION; BRAIN TISSUE; CAUDATE NUCLEUS; CEREBELLUM; CEREBELLUM CORTEX; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE SEVERITY; GENE FUNCTION; HUMAN; HUMAN CELL; HUMAN TISSUE; HUNTINGTON CHOREA; INHIBITION KINETICS; MITOCHONDRIAL RESPIRATION; PRIORITY JOURNAL; PUTAMEN; SKIN FIBROBLAST; SKIN TEST; SUBSTANTIA NIGRA;

BRAIN; BRAIN-DERIVED NEUROTROPHIC FACTOR; CYSTEINE ENDOPEPTIDASES; GENE EXPRESSION REGULATION; HUMANS; HUNTINGTON DISEASE; MULTIENZYME COMPLEXES; MUTATION; PROTEASOME ENDOPEPTIDASE COMPLEX; REGRESSION ANALYSIS; SKIN;

EID: 4444303263     PISSN: 03645134     EISSN: None     Source Type: Journal    
DOI: 10.1002/ana.20207     Document Type: Article

References (50)

1. Zoghbi HY, Orr HT. Glutamine repeats and neurodegeneration. Annu Rev Neurosci 2000;23:217-247.
2. Cummings CJ, Zoghbi HY. Trinucleotide repeats: mechanisms and pathophysiology. Annu Rev Genomics Hum Genet 2000; 1:281-328.
3. The Huntington's Disease Study Group. Group. A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. Cell 1993;72:971-983.
4. Snell RG, MacMillan JC, Cheadle JP, et al. Relationship between trinucleotide repeat expansion and phenotypic variation in Huntington's disease. Nat Genet 1993;4:393-397.
5. Perutz MF. Glutamine repeats and neurodegenerative diseases: molecular aspects. Trends Biochem Sci 1999;24:58-63.
6. Rubinsztein DC, Wyttenbach A, Rankin J. Intracellular inclusions, pathological markers in diseases caused by expanded polyglutamine tracts? J Med Genet 1999;36:265-270.
7. Heinsen H, Strik M, Bauer M, et al. Cortical and striatal neurone number in Huntington's disease. Acta Neuropathol (Berl) 1994;88:320-333,
8. Trottier Y, Devys D, Imbert G, et al. Cellular localization of the Huntington's disease protein and discrimination of the normal and mutated form. Nat Genet 1995;10:104-110.
9. Browne SE, Bowling AC, MacGarvey U, et al. Oxidative damage and metabolic dysfunction in Huntington's disease: selective vulnerability of the basal ganglia. Ann Neurol 1997;41: 646-653.
10. Panov AV, Gutekunst CA, Leavitt BR, et al. Early mitochondrial calcium defects in Huntington's disease are a direct effect of polyglutamines. Nat Neurosci 2002;5:731-736.
11. Beal MF. Energetics in the pathogenesis of neurodegenerative diseases. Trends Neurosci 2000;23:298-304.
12. Tabrizi SJ, Cleeter MW, Xuereb J, et al. Biochemical abnormalities and excitotoxicity in Huntington's disease brain. Ann Neurol 1999;45:25-32.
13. Kordower JH, Isacson O, Emerich DF. Cellular delivery of trophic factors for the treatment of Huntington's disease: is neuroprotection possible? Exp Neurol 1999;159:4-20.
14. Coyle JT, Schwarcz R. Lesion of striatal neurones with kainic acid provides a model for Huntington's chorea. Nature 1976; 263:244-246.
15. Abel A, Walcott J, Woods J, et al. Expression of expanded repeat androgen receptor produces neurologic disease in transgenic mice. Hum Mol Genet 2001;10:107-116.
16. Chai Y, Koppenhafer SL, Shoesmith SJ, et al. Evidence for proteasome involvement in polyglutamine disease: localization to nuclear inclusions in SCA3/MJD and suppression of polyglutamine aggregation in vitro. Hum Mol Genet 1999;8:673-682.
17. Schmidt T, Lindenberg KS, Krebs A, et al. Protein surveillance machinery in brains with spinocerebellar ataxia type 3: redistribution and differential recruitment of 26S proteasome subunits and chaperones to neuronal intranuclear inclusions. Ann Neurol 2002;51:302-310.
18. Bence NF, Sampat RM, Kopito RR. Impairment of the ubiquitin-proteasome system by protein aggregation. Science 2001;292:1552-1555.
19. Ardley HC, Scott GB, Rose SA, et al. Inhibition of proteasomal activity causes inclusion formation in neuronal and nonneuronal cells overexpressing Parkin. Mol Biol Cell 2003;14: 4541-4556.
20. Cummings CJ, Reinstein E, Sun Y, et al. Mutation of the E6-AP ubiquitin ligase reduces nuclear inclusion frequency while accelerating polyglutamine-induced pathology in SCA1 mice. Neuron 1999;24:879-892.
21. Davidson JD, Riley B, Burright EN, et al. Identification and characterization of an ataxin-1-interacting protein: A1Up, a ubiquitin-like nuclear protein. Hum Mol Genet 2000;9: 2305-2312.
22. McNaught KS, Olanow CW, Halliwell B, et al. Failure of the ubiquitin-proteasome system in Parkinson's disease. Nat Rev Neurosci 2001;2:589-594.
23. Lindsten K, de Vrij FM, Verhoef LG, et al. Mutant ubiquitin found in neurodegenerative disorders is a ubiquitin fusion degradation substrate that blocks proteasomal degradation. J Cell Biol 2002;157:417-427.
24. Ravikumar B, Duden R, Rubinsztein DC. Aggregate-prone proteins with polyglutamine and polyalanine expansions are degraded by autophagy. Hum Mol Genet 2002;11:1107-1117.
25. Takahashi R, Imai Y, Hattori N, Mizuno Y. Parkin and endoplasmic reticulum stress. Ann NY Acad Sci 2003;991:101-106.
26. Petrucelli L, O'Farrell C, Lockhart PJ, et al. Parkin protects against the toxicity associated with mutant alpha-synuclein: proteasome dysfunction selectively affects catecholaminergic neurons. Neuron 2002;36:1007-1019.
27. Zuccato C, Tartari M, Crotti A, et al. Huntingtin interacts with REST/NRSF to modulate the transcription of NRSE-controlled neuronal genes. Nat Genet 2003;35:76-83.
28. Zuccato C, Ciammola A, Rigamonti D, et al. Loss of huntingtin-mediated BDNF gene transcription in Huntington's disease. Science 2001;293:493-498.
29. Vonsattel JP, Myers RH, Stevens TJ, et al. Neuropathological classification of Huntington's disease. J Neuropathol Exp Neurol 1985;44:559-577.
30. Craiu A, Gaczynska M, Akopian T, et al. Lactacystin and clasto-lactacystin beta-lactone modify multiple proteasome beta-subunits and inhibit intracellular protein degradation and major histocompatibility complex class I antigen presentation. J Biol Chem 1997;272:13437-13445.
31. Pedersen PL, Greenawalt JW, Reynafarje B, et al. Preparation and characterization of mitochondria and submitochondrial particles of rat liver and liver-derived tissues. Methods Cell Biol 1978;20:411-481.
32. Groettrup M, Soza A, Eggers M, et al. A role for the proteasome regulator PA28alpha in antigen presentation. Nature 1996;381:166-168.
33. Schwarz K, Eggers M, Soza A, et al. The proteasome regulator PA28alpha/beta can enhance antigen presentation without affecting 20S proteasome subunit composition. Eur J Immunol 2000;30:3672-3679.
34. Zufferey R, Dull T, Mandel RJ, et al. Self-inactivating lentivirus vector for safe and efficient in vivo gene delivery. J Virol 1998;72:9873-9880.
35. Ferrer I, Goutan E, Marin C, et al. Brain-derived neurotrophic factor in Huntington disease. Brain Res 2000;866:257-261.
36. Gourfinkel-An I, Cancel G, Trottier Y, et al. Differential distribution of the normal and mutated forms of huntingtin in the human brain. Ann Neurol 1997;42:712-719.
37. Wyttenbach A, Carmichael J, Swartz J, et al. Effects of heat shock, heat shock protein 40 (HDJ-2), and proteasome inhibition on protein aggregation in cellular models of Huntington's disease. Proc Natl Acad Sci USA 2000;97:2898-2903.
38. de Almeida LP, Ross CA, Zala D, et al. Lentiviral-mediated delivery of mutant huntingtin in the striatum of rats induces a selective neuropathology modulated by polyglutamine repeat size, huntingtin expression levels, and protein length. J Neurosci 2002;22:3473-3483.
39. DeMartino GN, Slaughter CA. The proteasome, a novel protease regulated by multiple mechanisms. J Biol Chem 1999; 274:22123-22126.
40. Coux O, Tanaka K, Goldberg AL. Structure and functions of the 20S and 26S proteasomes. Annu Rev Biochem 1996;65:801-847.
41. Diaz-Hernandez M, Hernandez F, Martin-Aparicio E, et al. Neuronal induction of the immunoproteasome in Huntington's disease. J Neurosci 2003;23:11653-11661.
42. Ding Q, Lewis JJ, Strum KM, et al. Polyglutamine expansion, protein aggregation, proteasome activity, and neural survival. J Biol Chem 2002;277:13935-13942.
43. Snyder H, Mensah K, Theisler C, et al. Aggregated and monomeric alpha-synuclein bind to the S6′ proteasomal protein and inhibit proteasomal function. J Biol Chem 2003;278: 11753-11759.
44. Waelter S, Boeddrich A, Lurz R, et al. Accumulation of mutant huntingtin fragments in aggresome-like inclusion bodies as a result of insufficient protein degradation. Mol Biol Cell 2001; 12:1393-1407.
45. Haque NS, Isacson O. Neurotrophic factors NGF and FGF-2 alter levels of huntingtin (IT15) in striatal neuronal cell cultures. Cell Transplant 2000;9:623-627.
46. Canals JM, Checa N, Marco S, et al. Expression of brain-derived neurotrophic factor in cortical neurons is regulated by striatal target area. J Neurosci 2001;21:117-124.
47. Conner JM, Lauterborn JC, Yan Q, et al. Distribution of brain-derived neurotrophic factor (BDNF) protein and mRNA in the normal adult rat CNS: evidence for anterograde axonal transport. J Neurosci 1997;17:2295-2313.
48. Altar CA, Cai N, Bliven T, et al. Anterograde transport of brain-derived neurotrophic factor and its role in the brain. Nature 1997;389:856-860.
49. Bemelmans AP, Horellou P, Pradier L, et al. Brain-derived neurotrophic factor-mediated protection of striatal neurons in an excitotoxic rat model of Huntington's disease, as demonstrated by adenoviral gene transfer. Hum Gene Ther 1999;10:2987-2997.
50. Gu M, Gash MT, Mann VM, et al. Mitochondrial defect in Huntington's disease caudate nucleus. Ann Neurol 1996;39: 385-389.